Project Grant R01HL175463
Award Date
5/15/25
Completion Date
2/28/29
Dollars Obligated
$760K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $615,455 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Tennessee Health Science Center. The award will fund research to investigate the role of eosinophils, a type of white blood cell, in mediating antibacterial immunity against Streptococcus pneumoniae (pneumococcus) in the lungs. The project aims to elucidate the mechanisms by which eosinophils interact with and kill...
This $775,992 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in resolving acute lung injury and pneumonia. The project aims to determine how Treg glucocorticoid receptor signaling affects Treg function and the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune cell crosstalk and its impact on lung injury, fibrosis, and host defense against infections. The key objectives of this 7-year project are to: 1) study how epithelial cell signaling via heparin-binding EGF-like growth factor (HB-EGF) regulates fibrosis...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $759,025 to the University of North Carolina at Chapel Hill to conduct research on the functions of the ICAM-1 protein in the lungs during homeostasis and innate immune responses. The key objectives are to determine the roles of soluble ICAM-1 and cell-specific ICAM-1 expression in processes like leukocyte trafficking and immune cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $373,500 to the University of Southern California to conduct a secondary analysis of existing datasets. The goal is to define the neutrophil transcriptomic response to parenchymal damage, which is associated with multiple organ failure in conditions like septic shock, major surgery, and traumatic injury. The project aims to...
This Project Grant award for $755,228.26 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish the mechanisms by which the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) modulates immune regulation and tissue recovery during pneumonia. The award to the University of Iowa will support research to elucidate how LOX-1 signaling in leukocytes (such as alveolar macrophages and recruited...
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The award supports research to investigate indole metabolites as novel danger signals that activate regulated cell death pathways and innate immune responses in lung epithelial cells, and their potential role in the pathogenesis of acute respiratory distress syndrome (ARDS). The research aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996.00 to the University of Southern California (USC) to conduct research on the role of the protein PDLIM2 in alveolar macrophage function and its impact on lung immunity, inflammation, and diseases. The research aims to determine how PDLIM2 regulates alveolar macrophage phagocytosis, immune response, and vulnerability...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the functional role of lung microfold (M) cells in predisposition to influenza-associated pneumococcal invasion and pneumonia. The $342,900 award, with a performance period from September 1, 2024 to September 30, 2026, aims to investigate the intracellular trafficking mechanisms during pneumococcal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the mechanisms by which tissue-resident lymphocytes suppress alveolar stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). The research aims to uncover therapeutic approaches to attenuate the frequent...